Oncology (all articles)
Guidelines for Management of Patients with Anaplastic Thyroid Cancer
20 Apr, 2021 | 05:24h | UTCCommentary: ATA Issues Guidelines for Managing Anaplastic Thyroid Cancer – HealthDay
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review
18 Apr, 2021 | 21:16h | UTC
M-A: Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy
18 Apr, 2021 | 21:14h | UTC
RCT: Better continence after 3 months with robotic-assisted compared with laparoscopic radical prostatectomy
18 Apr, 2021 | 21:11h | UTCRobotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01)https://t.co/YenifaBnfe@doguteber @Hohenfellner pic.twitter.com/kfpQc1u0xf
— European Urology (@EUplatinum) February 11, 2021
RCT: An Enhanced Recovery After Surgery (ERAS) program in laparoscopic distal gastrectomy provided a faster recovery, a shorter postoperative hospitalization length, and lower medical costs without increasing complication and readmission rates
16 Apr, 2021 | 06:16h | UTCRelated: Consensus guidelines for enhanced recovery after gastrectomy – British Journal of Surgery AND Current status of the “enhanced recovery after surgery” program in gastric cancer surgery – Annals of Gastroenterological Surgery
See also: Enhanced Recovery After Surgery (ERAS) Society Guidelines
M-A: Chemotherapy and radiotherapy in locally advanced head and neck cancer
15 Apr, 2021 | 06:29h | UTC
Commentary on Twitter
What is the best treatment in locally advanced HN Cancer?
Our latest individual patient data network meta-analysis available here for free @TheLancetOncol: https://t.co/UuFvjpKO6I
Many limitations but by far the largest work on the topic (115 RCT, 29000 pts).
#radonc #hncsm pic.twitter.com/eNYHbxsB4Q
— Pierre Blanchard, MD (@PBlanchardMD) April 14, 2021
Review: Endocrine complications of immunotherapies
15 Apr, 2021 | 06:13h | UTCEndocrine complications of immunotherapies: a review – Clinical Medicine Journal
RCT: Low-dose aspirin safely suppresses the recurrence of colorectal polyps in patients with familial adenomatous polyposis
14 Apr, 2021 | 01:49h | UTCChemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Ishikawa et al – Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a randomised, 2×2 factorial trialhttps://t.co/NJ4b77p591#gitwitter #FAP #crcsm
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 2, 2021
Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management
14 Apr, 2021 | 01:27h | UTC
Perspective: Special diets might boost the power of drugs to vanquish cancers
8 Apr, 2021 | 08:43h | UTCSpecial diets might boost the power of drugs to vanquish cancers – Science
Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation
9 Apr, 2021 | 03:09h | UTCCancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation – JCO Global Oncology
RCT: Celecoxib for 3 years added to standard adjuvant therapy does not improve disease-free survival among patients with stage III colon cancer
7 Apr, 2021 | 01:28h | UTCEffect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Celecoxib for Stage III Colon Cancer – JAMA (free for a limited period)
Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery
6 Apr, 2021 | 01:01h | UTCGuide to Enhanced Recovery for Cancer Patients Undergoing Surgery – Annals of Surgical Oncology
See also: Enhanced Recovery After Surgery (ERAS) Society Guidelines
Recent progress in the treatment of cancer in children
5 Apr, 2021 | 01:15h | UTCRecent progress in the treatment of cancer in children – CA: A Cancer Journal for Clinicians
Cohort study: High thrombotic risk in cancer patients receiving immunotherapy
5 Apr, 2021 | 01:08h | UTCHigh thrombotic risk in cancer patients receiving immunotherapy – Medical University of Vienna
Original study: Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy – Blood
M-A: Similar oncological outcomes with laparoscopic vs. open rectal cancer resections
5 Apr, 2021 | 00:43h | UTC
Preliminary study finds a low-calorie diet and mild exercise may improve survival for young people with leukemia
2 Apr, 2021 | 09:12h | UTC
RCT: Second-line FOLFOX chemotherapy vs. active symptom control for advanced biliary tract cancer
1 Apr, 2021 | 03:21h | UTCCommentary: Treating patients with advanced biliary tract cancers: Changing tactics – Cancer Research UK
RCT: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
1 Apr, 2021 | 03:19h | UTCAdjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Clinical Review: Immunotherapy Management in Special Cancer Patient Populations
31 Mar, 2021 | 02:59h | UTCImmunotherapy Management in Special Cancer Patient Populations – JCO Oncology Practice
Evolution of the randomized clinical trial in the era of precision oncology
26 Mar, 2021 | 08:35h | UTCEvolution of the Randomized Clinical Trial in the Era of Precision Oncology – JAMA Oncology
Commentary on Twitter
Food for thoughts: randomized clinical trials in the era of precision oncology
➡️PFS, not OS predominant endpoint
➡️Modest median survival gains
➡️Almost all industry funded
➡️Substantial increase in use of professional medical writers#radonchttps://t.co/k92MEs1eWR— Matthias Guckenberger (@Mat_Guc) March 25, 2021
FDA approval standards for anticancer agents — lessons from two recent approvals in breast cancer
26 Mar, 2021 | 08:30h | UTC
Commentary on Twitter
Our paper published today in @NatRevClinOncol discussing the dropping of bar for approval of cancer drugs. These two examples highlight why we all should seriously be concerned about this low bar. https://t.co/T27QI00dj2 pic.twitter.com/26Df3fJsoD
— Bishal Gyawali, MD, PhD, FASCO (@oncology_bg) March 25, 2021
Diagnosing and treating brain tumors: reflections on the latest Cochrane evidence
19 Mar, 2021 | 08:06h | UTC
RCT: No benefit from palliative radiotherapy after esophageal cancer stenting
18 Mar, 2021 | 08:52h | UTC
[Preprint] Delaying second vaccine dose leaves cancer patients vulnerable to virus
17 Mar, 2021 | 02:58h | UTCNews release: Delaying second vaccine dose leaves cancer patients vulnerable to virus – King’s College London
Commentaries: Expert reaction to preprint looking at antibody immune response following one dose of Pfizer COVID-19 vaccine in cancer patients – Science Media Centre AND Cancer patients ‘lack same protection’ after first jab – BBC